150 related articles for article (PubMed ID: 12672249)
1. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Lubczyk V; Bachmann H; Gust R
J Med Chem; 2003 Apr; 46(8):1484-91. PubMed ID: 12672249
[TBL] [Abstract][Full Text] [Related]
2. Invesgations [correction investigations] on the influence of halide substituents on the estrogen receptor interaction of 2, 4, 5-tris(4-hydroxyphenyl)imidazoles.
Gust R; Busch S; Keilitz R; Schmidt K; Von Rauch M
Arch Pharm (Weinheim); 2003 Oct; 336(10):456-65. PubMed ID: 14582122
[TBL] [Abstract][Full Text] [Related]
3. Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Lubczyk V; Bachmann H; Gust R
J Med Chem; 2002 Nov; 45(24):5358-64. PubMed ID: 12431063
[TBL] [Abstract][Full Text] [Related]
4. Effects of C2-alkylation, N-alkylation, and N,N'-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
von Rauch M; Schlenk M; Gust R
J Med Chem; 2004 Feb; 47(4):915-27. PubMed ID: 14761193
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties.
Gust R; Lubczyk V
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):57-70. PubMed ID: 12943745
[TBL] [Abstract][Full Text] [Related]
6. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
von Rauch M; Busch S; Gust R
J Med Chem; 2005 Jan; 48(2):466-74. PubMed ID: 15658860
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, structural evaluation, and estrogen receptor interaction of 4,5-bis(4-hydroxyphenyl)imidazoles.
Gust R; Keilitz R; Schmidt K; von Rauch M
Arch Pharm (Weinheim); 2002 Dec; 335(10):463-71. PubMed ID: 12506394
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
9. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
Gust R; Niebler K; Schönenberger H
J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles.
Wiglenda T; Gust R
J Med Chem; 2007 Apr; 50(7):1475-84. PubMed ID: 17352461
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
12. Dibenzo[a,g]quinolizin-8-ones: synthesis, estrogen receptor affinities, and cytostatic activity.
von Angerer S; Brandl G; Mannschreck A; Weimar C; Wiegrebe W
Anticancer Drug Des; 1992 Oct; 7(5):351-63. PubMed ID: 1388628
[TBL] [Abstract][Full Text] [Related]
13. Structure activity relationship studies on C2 side chain substituted 1,1-bis(4-methoxyphenyl)-2-phenylalkenes and 1,1,2-tris(4-methoxyphenyl)alkenes.
Gust R; Lubczyk V
J Steroid Biochem Mol Biol; 2003 Oct; 87(1):75-83. PubMed ID: 14630093
[TBL] [Abstract][Full Text] [Related]
14. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
17. Stilbene-based inhibitors of estrone sulfatase with a dual mode of action in human breast cancer cells.
Walter G; Liebl R; von Angerer E
Arch Pharm (Weinheim); 2004 Dec; 337(12):634-44. PubMed ID: 15597397
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
19. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha.
Zimmermann J; Liebl R; von Angerer E
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):57-66. PubMed ID: 15862950
[TBL] [Abstract][Full Text] [Related]
20. (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode.
Gust R; Keilitz R; Schmidt K; von Rauch M
J Med Chem; 2002 Aug; 45(16):3356-65. PubMed ID: 12139447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
